Last reviewed · How we verify
NPC-15
NPC-15 is a small molecule that targets the SGLT2 receptor.
NPC-15 is a small molecule that targets the SGLT2 receptor. Used for Treatment of type 2 diabetes.
At a glance
| Generic name | NPC-15 |
|---|---|
| Also known as | Melatonin |
| Sponsor | Nobelpharma |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
NPC-15 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders (PHASE3)
- Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders (PHASE2, PHASE3)
- Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPC-15 CI brief — competitive landscape report
- NPC-15 updates RSS · CI watch RSS
- Nobelpharma portfolio CI